BMS-936559, Avelumab, MEDI4736, and, Atezolizumab are the anti-PD-L1 antibodies that are being studied for various cancers and tumors including melanoma, multiple myeloma, leukemia, lymphoma, glioblastoma as well as gastric, renal cell, bladder, colorectal, hepatocellular, cutaneous, breast and NSCLC (Non-Small Cell Lung Cancer) cancers, (CRC), castration-resistant prostate cancer (CRPC), renal cell carcinoma (RCC), head and neck squamous cell cancer (HNSCC). This evidence concerns the gene CD274 and renal cell adenocarcinoma.